Open-label, Multicenter, Non-Comparative, Prospective Observational Study to Evaluate Efficacy and Safety of Combined Ribavirin and Peginterferon Alfa-2a (40 kDa) Therapy in Patients With Chronic Hepatitis C (CHC) or Compensated Liver Cirrhosis in Real Clinical Practice

Trial Profile

Open-label, Multicenter, Non-Comparative, Prospective Observational Study to Evaluate Efficacy and Safety of Combined Ribavirin and Peginterferon Alfa-2a (40 kDa) Therapy in Patients With Chronic Hepatitis C (CHC) or Compensated Liver Cirrhosis in Real Clinical Practice

Completed
Phase of Trial: Phase IV

Latest Information Update: 18 Apr 2017

At a glance

  • Drugs Peginterferon alfa-2a (Primary) ; Ribavirin
  • Indications Hepatitis C; Liver cirrhosis
  • Focus Therapeutic Use
  • Acronyms STANDART
  • Sponsors Roche
  • Most Recent Events

    • 01 Dec 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 01 Sep 2015 Planned End Date changed from 1 Aug 2015 to 1 Dec 2015, as reported by ClinicalTrials.gov.
    • 01 Sep 2015 Planned primary completion date changed from 1 Aug 2015 to 1 Dec 2015, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top